Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EASL 2014: Hepatitis C players seek the spotlight

This article was originally published in Scrip

Executive Summary

The new Gilead Sciences blockbuster hepatitis C drug Sovaldi may be the star of the show at the 49th Annual Meeting of the European Association of the Study of the Liver (EASL) from 9 to 13 April in London, but AbbVie, Merck & Co and others will snag their own share of the spotlight.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts